Immutep (IMMP) details EFTISARC-NEO Phase II data from CTOS 2025

Rhea-AI Filing Summary

Immutep Limited furnished a Form 6-K that attaches an exhibit summarizing translational data and significant pathologic response rates from its EFTISARC-NEO Phase II study. These results were highlighted in an oral presentation at the CTOS 2025 conference, and the filing formally submits that presentation information to U.S. investors.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as November 13, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 13, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What does Immutep (IMMP) report in this Form 6-K filing?

Immutep reports that it has furnished an exhibit containing translational data and significant pathologic response rates from its EFTISARC-NEO Phase II study, which were highlighted in an oral presentation at the CTOS 2025 conference for investor and regulatory transparency.

What is the key exhibit attached to Immutep’s Form 6-K for IMMP?

The key exhibit is 99.1, titled “Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025,” providing investors access to the scientific and clinical information presented at that conference session.

Which clinical study is referenced in Immutep’s latest Form 6-K for IMMP?

The filing references the EFTISARC-NEO Phase II study. Immutep’s Form 6-K notes that translational data and significant pathologic response rates from this trial were highlighted in an oral presentation at the CTOS 2025 conference and furnished as Exhibit 99.1.

How are EFTISARC-NEO Phase II results shared with Immutep (IMMP) investors?

EFTISARC-NEO Phase II results are shared through Exhibit 99.1 to the Form 6-K, which contains translational data and significant pathologic response rates that were previously highlighted in an oral presentation at the CTOS 2025 conference, making that information available in regulatory form.

What is the significance of CTOS 2025 in Immutep’s IMMP Form 6-K?

CTOS 2025 is the conference where Immutep’s EFTISARC-NEO Phase II translational data and significant pathologic response rates were highlighted in an oral presentation. The Form 6-K furnishes the related exhibit so these conference materials are also available through U.S. securities disclosures.